JPWO2020120450A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2020120450A5 JPWO2020120450A5 JP2021533340A JP2021533340A JPWO2020120450A5 JP WO2020120450 A5 JPWO2020120450 A5 JP WO2020120450A5 JP 2021533340 A JP2021533340 A JP 2021533340A JP 2021533340 A JP2021533340 A JP 2021533340A JP WO2020120450 A5 JPWO2020120450 A5 JP WO2020120450A5
- Authority
- JP
- Japan
- Prior art keywords
- disorders
- disease
- disorder
- fluoro
- pharmaceutical composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 125000001153 fluoro group Chemical group F* 0.000 claims 7
- 150000001875 compounds Chemical class 0.000 claims 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 4
- 229910052739 hydrogen Inorganic materials 0.000 claims 4
- 239000001257 hydrogen Substances 0.000 claims 4
- 239000008194 pharmaceutical composition Substances 0.000 claims 4
- 208000000044 Amnesia Diseases 0.000 claims 3
- 208000035475 disorder Diseases 0.000 claims 3
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 3
- 208000024827 Alzheimer disease Diseases 0.000 claims 2
- 208000031091 Amnestic disease Diseases 0.000 claims 2
- 208000019901 Anxiety disease Diseases 0.000 claims 2
- 208000023105 Huntington disease Diseases 0.000 claims 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 2
- 206010041250 Social phobia Diseases 0.000 claims 2
- 102000003621 TRPC5 Human genes 0.000 claims 2
- 101150042815 TRPC5 gene Proteins 0.000 claims 2
- 230000006986 amnesia Effects 0.000 claims 2
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims 2
- 150000002431 hydrogen Chemical class 0.000 claims 2
- 208000014674 injury Diseases 0.000 claims 2
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 claims 2
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims 2
- 208000024714 major depressive disease Diseases 0.000 claims 2
- 230000000626 neurodegenerative effect Effects 0.000 claims 2
- 230000000926 neurological effect Effects 0.000 claims 2
- 208000028173 post-traumatic stress disease Diseases 0.000 claims 2
- 150000003839 salts Chemical class 0.000 claims 2
- 208000008811 Agoraphobia Diseases 0.000 claims 1
- 208000025978 Athletic injury Diseases 0.000 claims 1
- 208000020925 Bipolar disease Diseases 0.000 claims 1
- 208000003174 Brain Neoplasms Diseases 0.000 claims 1
- 208000014644 Brain disease Diseases 0.000 claims 1
- 206010008874 Chronic Fatigue Syndrome Diseases 0.000 claims 1
- 208000020406 Creutzfeldt Jacob disease Diseases 0.000 claims 1
- 208000003407 Creutzfeldt-Jakob Syndrome Diseases 0.000 claims 1
- 208000010859 Creutzfeldt-Jakob disease Diseases 0.000 claims 1
- 206010012335 Dependence Diseases 0.000 claims 1
- 208000026331 Disruptive, Impulse Control, and Conduct disease Diseases 0.000 claims 1
- 208000025967 Dissociative Identity disease Diseases 0.000 claims 1
- 208000011688 Generalised anxiety disease Diseases 0.000 claims 1
- 208000030990 Impulse-control disease Diseases 0.000 claims 1
- 208000006264 Korsakoff syndrome Diseases 0.000 claims 1
- 208000020358 Learning disease Diseases 0.000 claims 1
- 208000026139 Memory disease Diseases 0.000 claims 1
- 208000021384 Obsessive-Compulsive disease Diseases 0.000 claims 1
- 208000002193 Pain Diseases 0.000 claims 1
- 208000018737 Parkinson disease Diseases 0.000 claims 1
- 201000009916 Postpartum depression Diseases 0.000 claims 1
- 208000000810 Separation Anxiety Diseases 0.000 claims 1
- 108010037150 Transient Receptor Potential Channels Proteins 0.000 claims 1
- 102000011753 Transient Receptor Potential Channels Human genes 0.000 claims 1
- 201000008485 Wernicke-Korsakoff syndrome Diseases 0.000 claims 1
- 208000027418 Wounds and injury Diseases 0.000 claims 1
- 230000032683 aging Effects 0.000 claims 1
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 claims 1
- 230000036506 anxiety Effects 0.000 claims 1
- 201000007201 aphasia Diseases 0.000 claims 1
- 208000030963 borderline personality disease Diseases 0.000 claims 1
- 208000029028 brain injury Diseases 0.000 claims 1
- 230000006378 damage Effects 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 206010013461 dissociative amnesia Diseases 0.000 claims 1
- 230000008482 dysregulation Effects 0.000 claims 1
- 208000024732 dysthymic disease Diseases 0.000 claims 1
- 230000000694 effects Effects 0.000 claims 1
- 230000002996 emotional effect Effects 0.000 claims 1
- 208000029364 generalized anxiety disease Diseases 0.000 claims 1
- 230000005764 inhibitory process Effects 0.000 claims 1
- 201000003723 learning disability Diseases 0.000 claims 1
- 230000001404 mediated effect Effects 0.000 claims 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 1
- 208000029766 myalgic encephalomeyelitis/chronic fatigue syndrome Diseases 0.000 claims 1
- 208000019906 panic disease Diseases 0.000 claims 1
- 201000000980 schizophrenia Diseases 0.000 claims 1
- 208000019116 sleep disease Diseases 0.000 claims 1
- 208000023516 stroke disease Diseases 0.000 claims 1
- 230000001225 therapeutic effect Effects 0.000 claims 1
- 230000008733 trauma Effects 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP18212060.0 | 2018-12-12 | ||
| EP18212060 | 2018-12-12 | ||
| PCT/EP2019/084375 WO2020120450A1 (en) | 2018-12-12 | 2019-12-10 | Substituted xanthine derivatives |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2022512373A JP2022512373A (ja) | 2022-02-03 |
| JPWO2020120450A5 true JPWO2020120450A5 (enrdf_load_stackoverflow) | 2022-12-16 |
| JP7502299B2 JP7502299B2 (ja) | 2024-06-18 |
Family
ID=64665184
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021533340A Active JP7502299B2 (ja) | 2018-12-12 | 2019-12-10 | 置換キサンチン誘導体 |
Country Status (19)
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US12064917B2 (en) | 2012-11-21 | 2024-08-20 | Stratasys, Inc. | Method for printing three-dimensional parts with cyrstallization kinetics control |
| CN113166151B (zh) * | 2018-12-12 | 2023-12-01 | 勃林格殷格翰国际有限公司 | 经取代的黄嘌呤衍生物 |
| CN118459461A (zh) * | 2023-02-08 | 2024-08-09 | 中国科学院上海药物研究所 | 黄嘌呤类化合物及其用途 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EA028815B1 (ru) | 2013-03-15 | 2018-01-31 | Хайдра Байосайенсиз, Инк. | Замещенные ксантины и способы их применения |
| JP6667093B2 (ja) | 2014-08-11 | 2020-03-18 | ハイドラ・バイオサイエンシーズ・リミテッド・ライアビリティ・カンパニーＨｙｄｒａ Ｂｉｏｓｃｉｅｎｃｅｓ， ＬＬＣ | ピリド［２，３−ｄ］ピリミジン−２，４（１Ｈ，３Ｈ）−ジオン誘導体 |
| GB201702160D0 (en) | 2017-02-09 | 2017-03-29 | Univ Leeds Innovations Ltd | Inhibitors for use in therapy |
| LT3652176T (lt) * | 2017-07-11 | 2022-02-25 | Boehringer Ingelheim International Gmbh | Pakeisti ksantino dariniai |
| CN113166151B (zh) * | 2018-12-12 | 2023-12-01 | 勃林格殷格翰国际有限公司 | 经取代的黄嘌呤衍生物 |
-
2019
- 2019-12-10 CN CN201980081737.1A patent/CN113166151B/zh active Active
- 2019-12-10 PH PH1/2021/551345A patent/PH12021551345A1/en unknown
- 2019-12-10 MX MX2021007019A patent/MX2021007019A/es unknown
- 2019-12-10 EA EA202191588A patent/EA202191588A1/ru unknown
- 2019-12-10 EP EP19820718.5A patent/EP3894410B1/en active Active
- 2019-12-10 WO PCT/EP2019/084375 patent/WO2020120450A1/en unknown
- 2019-12-10 BR BR112021008316-2A patent/BR112021008316A2/pt unknown
- 2019-12-10 AU AU2019396499A patent/AU2019396499B2/en active Active
- 2019-12-10 IL IL283768A patent/IL283768B2/en unknown
- 2019-12-10 DK DK19820718.5T patent/DK3894410T3/da active
- 2019-12-10 CA CA3119229A patent/CA3119229A1/en active Pending
- 2019-12-10 HU HUE19820718A patent/HUE064908T2/hu unknown
- 2019-12-10 KR KR1020217021875A patent/KR20210102955A/ko active Pending
- 2019-12-10 PL PL19820718.5T patent/PL3894410T3/pl unknown
- 2019-12-10 JP JP2021533340A patent/JP7502299B2/ja active Active
- 2019-12-10 ES ES19820718T patent/ES2964630T3/es active Active
- 2019-12-11 US US16/710,887 patent/US11198696B2/en active Active
- 2019-12-12 TW TW108145593A patent/TWI825243B/zh active
-
2021
- 2021-06-09 CL CL2021001509A patent/CL2021001509A1/es unknown
- 2021-11-10 US US17/523,316 patent/US20220177479A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2022017447A5 (enrdf_load_stackoverflow) | ||
| RU2015143466A (ru) | Нейроактивные стероиды и способы их применения | |
| RU2417225C2 (ru) | Индазолы, бензотиазолы, бензоизотиазолы, бензизоксазолы и их получение и применение | |
| HRP20220029T1 (hr) | Supstituirani derivati ksantina | |
| JP2018508592A5 (enrdf_load_stackoverflow) | ||
| JP2019525939A5 (enrdf_load_stackoverflow) | ||
| JP2005539012A5 (enrdf_load_stackoverflow) | ||
| EA202090987A8 (ru) | Новые пролекарства на основе катехоламина для применения в лечении болезни паркинсона | |
| ECSP045289A (es) | Amidas sustituidas | |
| JP2016513663A5 (enrdf_load_stackoverflow) | ||
| JP2007500757A5 (enrdf_load_stackoverflow) | ||
| JP2020526591A5 (enrdf_load_stackoverflow) | ||
| BR112019004243A2 (pt) | composto, composição farmacêutica, método para inibição de quinase do zíper de leucina dupla, método para tratamento de uma doença mediada por quinase do zíper de leucina dupla e método para obter um efeito em um paciente | |
| MXPA05012391A (es) | Tratamiento de trastornos psicoticos y depresivos. | |
| JP2020504156A5 (enrdf_load_stackoverflow) | ||
| EP2590936B1 (en) | Phenylcarbamate compound and muscle relaxant containing the same | |
| JPWO2020120450A5 (enrdf_load_stackoverflow) | ||
| RU2013124827A (ru) | Производные индола и способ их получения | |
| RU2012104856A (ru) | 3-феноксиметилпирролидиновые соединения | |
| JP2017525684A5 (enrdf_load_stackoverflow) | ||
| RU2019128576A (ru) | Сокристаллы замещенных глициновых соединений и их применение | |
| JPWO2020120449A5 (enrdf_load_stackoverflow) | ||
| RU2011107443A (ru) | Индаценовые соединения, фармацевтическая композиция и лекарственное средство на их основе, способ их получения и способ лечения или профилактики состояний, связанных с нарушением функционирования систем, регулируемых мелатонином, с их помощью | |
| JP2019535715A5 (enrdf_load_stackoverflow) | ||
| JP2023539291A (ja) | 神経変性疾患の予防又は治療用フェニルアルキルカルバメート化合物 |